Peter C. Farrell
PhD, DSc, AM – Executive Chairman of the Board
Peter Farrell has served as ResMed's Executive Chairman of the Board since January 1, 2008. He has been a director of the Company since June 1989 and served as Chief Executive Officer from July 1990 until December 2007. From ResMed’s inception until September 2004, Dr. Farrell was also ResMed’s President.
From July 1984 to June 1989, Dr. Farrell served as Vice President, Research and Development at various subsidiaries of Baxter International, Inc. (“Baxter”), and from August 1985 to June 1989, he also served as Managing Director of the Baxter Center for Medical Research Pty Ltd., a subsidiary of Baxter. From January 1978 to December 1989, he was Foundation Director of the Center (now Graduate School) for Biomedical Engineering at the University of New South Wales where he currently serves as a Visiting Professor.
He holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle and a D.Sc. from the University of New South Wales.
Dr. Farrell was named 1998 San Diego Entrepreneur of the Year for Health Sciences, Australian Entrepreneur of the Year in 2001 and US National Entrepreneur of the Year for 2005 in Health Sciences. In August 2000, he was named Vice Chairman of the Executive Council of the Harvard Medical School Division of Sleep Medicine. In addition to his responsibilities with ResMed, Dr. Farrell is a director of NuVasive, Inc., a NASDAQ-listed company that develops and markets products for the surgical treatment of spine disorders; Pharmaxis Limited, an ASX and NASDAQ-listed specialist pharmaceutical company, and is the non-executive chair of QRxPharma, a clinical-stage specialty pharmaceutical company listed on the ASX. He is a Fellow or Honorary Fellow of several professional bodies.
Kieran T. Gallahue
President and Chief Executive Officer
Kieran T. Gallahue has served as our Chief Executive Officer and director since January 1, 2008 and has been our President since September 2004. He began his career at ResMed in January 2003 as President and Chief Operating Officer of the Americas.
Before joining ResMed, Mr. Gallahue served as President of Nanogen, Inc., a San Diego-based DNA research and medical diagnostics company. Mr. Gallahue also held roles of Chief Financial Officer and Vice President of Strategic Marketing for Nanogen. From 1995 to 1997 he served as Vice President of the Critical Care Business Unit for Instrumentation Laboratory, or IL. Before 1995, Mr. Gallahue held various marketing, sales and financial positions within IL, Procter & Gamble and GE. Mr. Gallahue holds a B.A. from Rutgers University and an M.B.A. from Harvard Business School.
Stein Jacobsen
Chief Operating Officer (COO) - Europe
Stein Jacobsen has served as ResMed’s Chief Operating Officer - Europe since January 1, 2009. He joined ResMed in 2005 as Chief Operating Officer – Nordics, after the company’s acquisition of PolarMed Holding AS, a Scandinavian medical equipment distributor that Mr. Jacobsen founded in 1993. Mr Jacobsen served as COO – Nordics until July 2007, when he became Senior Vice President of ResMed’s Ventilation Strategic Business Unit. He continues to lead the Ventilation Strategic Business Unit in addition to his responsibilities as COO - Europe.
With over 20 years’ experience in the respiratory business, Mr Jacobsen has founded and directed eight successful medical equipment distributors in the Scandinavian respiratory market. Mr Jacobsen holds the equivalent of a B.Sc. in Clinical Engineering from the University of Stavanger, Norway.
Robert Douglas
Chief Operating Officer (COO) - Asia Pacific
Rob was appointed as COO - Asia Pacific in July 2008. This appointment follows an extensive career within ResMed, his former roles including COO – Sydney from 2005 and Vice President of Operations from 2003 responsible for ResMed’s Australian manufacturing. Rob first joined ResMed In 2001 in the role of Vice President of Corporate Marketing.
Before joining ResMed in 2001, and beginning in 1995, Mr. Douglas was the General Manager, Strategy and New Business for Keycorp Ltd., an Australian electronic commerce company providing services to major banks and telecommunications companies around the world. Before Keycorp, he held senior R & D and operational roles in Telectronics Pty Ltd., mainly working on the development of an implantable defibrillator. Mr. Douglas sits on the Board of Directors of Colocare, a private startup medical device company unrelated to ResMed. Mr. Douglas has an M.B.A. from Macquarie University and a B.S. in Electrical Engineering and Computer Sciences from New South Wales University, Sydney.
David Pendarvis
Sr. Vice President, Organizational Development
David has been Sr. VP Organisational Development since February 2005. Mr. Pendarvis has been Global General Counsel since he joined ResMed in September 2002, and from February 2003, has been Corporate Secretary.
From September 2000 until September 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP, where he specialized in intellectual property and general business litigation. Until September 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis holds a B.A. from Rice University; a J.D., cum laude, from the University of Texas School of Law; and a Masters of Science in Executive Leadership from the University of San Diego.
Brett Sandercock
Chief Financial Officer (CFO)
Brett has been CFO since January 1, 2006. From November 2004 until January 1, 2006, Mr. Sandercock was Vice President, Treasury and Finance. Before that, and beginning in 1998, Mr. Sandercock was Group Accountant and then Controller.
From March 1996 to August 1998 he was Manager, Financial Accounting and Group Reporting at Norton Abrasives, a division of the French multi-national, Saint Gobain. Mr. Sandercock also held finance and accounting roles from November 1994 to March 1996 at Health Care of Australia, a large private hospital operator in Australia. From 1989 to 1994, Mr. Sandercock worked at PricewaterhouseCoopers in Sydney, achieving the position of audit manager. Mr. Sandercock holds a B.Ec. from Macquarie University and is a Certified Chartered Accountant.